+368.8%
SNXX vs MRNA
+199.4%
+169.4%
-85.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.1% | +5.4% | -12.4% | -7.0% |
| 7D | -12.0% | -1.1% | -11.0% | -12.0% |
| 30D | +37.9% | +126.1% | -88.2% | +42.7% |
| 3M | -52.7% | +190.0% | -242.7% | -61.1% |
| 6M | +194.8% | +157.2% | +37.6% | +156.3% |
| All | +368.8% | +199.4% | +169.4% | +406.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling